6533b81ffe1ef96bd1277a16

RESEARCH PRODUCT

Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk Acute Myeloid leukemia: a 3-Years Follow-Up

Gerhard HeilW. LangerW. BrockhausKlaus HöffkenM. KlausmannAlexander KnuthOliver G. OttmannKarin KolbeT. H. IttelH. G. FuhrC. ZanderJ. Th. FischerW.-k. HofmannG. SeipeltLothar BergmannDieter HoelzerArnold GanserN. Brack

subject

Interleukin 2Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMyeloid leukemiaImmunotherapyCytokinehemic and lymphatic diseasesInternal medicinemedicineIdarubicinbusinessAmsacrineARA-C/VP-16medicine.drug

description

To improve the complete remission (CR) rate and to prolong CR duration in patients with advanced MDS, AML evolving from MDS, and secondary AML, a phase-III trial of aggressive chemotherapy followed by G-CSF was initiated in January 1992. Pts. achieving a CR were randomized to receive either high-dose or low-dose IL-2 to evaluate the potential of this cytokine to eliminate residual leukemic cells and to prolong the CR duration.

yearjournalcountryeditionlanguage
1998-01-01
https://doi.org/10.1007/978-3-642-71960-8_113